+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06710210

Comparing a Bioresorbable Scaffold with Drug-coated Balloons Versus Drug-Eluting Stents for Treating Long and Diffuse Coronary Artery Disease in PCI Patients The BIOHYBRID Randomized Pilot Trial

Led by University Hospital, Geneva · Updated on 2026-09-02

150

Participants Needed

4

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating two strategies for treating patients with long and diffuse coronary artery disease undergoing percutaneous coronary intervention PCI. The study compares a hybrid PCI approach using a bioresorbable magnesium-based sirolimus-eluting scaffold combined with one or more paclitaxel-eluting drug-coated balloons against a conventional PCI approach using newer-generation drug-eluting stents. The goal is to assess safety and effectiveness by measuring changes in vessel function using non-invasive angiography-derived fractional flow reserve FFRangio over 12 months. Participants receive either the hybrid PCI treatment involving a magnesium-based bioresorbable scaffold and drug-coated balloons or the conventional PCI treatment with multiple newer-generation drug-eluting stents. The study focuses on patients with long andor diffuse coronary lesions suitable for PCI. The hybrid approach aims to minimize permanent metal left in the artery by combining temporary scaffolding and drug delivery. Treatments are delivered during the initial PCI procedure, followed by regular monitoring. During the study, participants undergo assessments including non-invasive FFRangio measurements immediately after PCI and at 12 months to evaluate vessel function. Researchers monitor target vessel failure rates and collect data on safety and efficacy outcomes. Participants are expected to comply with dual antiplatelet therapy for at least six months and attend follow-up visits including a control coronary angiogram at 12 months. The total participation duration spans from the initial PCI to 12 months of follow-up.

CONDITIONS

Brief Title

Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease

Research Team

J

Juan F Iglesias, Principal Investigator

C

Charlotte Kisgen, Study Coordinator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here